Skip to main content

Table 2 Achievement of Clinical Inactive Disease (CID) off Glucocorticoids (GC) in Non-Biologic and Biologic initiated patients (primary endpoint), as well as in the 4 Consensus Treatment Plan (CTP) groups

From: Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans

  Biologic grouping
Patient Status at Month 9 Total N = 30 Gluco-corticoids N = 2 Methotrex-ate N = 6 IL1ia N = 12 IL6ia N = 10 p-value Non-Biologic CTP N = 8 Biologic CTP N = 22 p-value
CID 13/30 (43.3%) 0/2 2/6 (33.3%) 5/12 (41.7%) 6/10 (60.0%) 0.549 2/8 (25.0%) 11/22 (50.0%) 0.407
Off GC 20/30 (66.7%) 1/2 (50.0%) 1/6 (16.7%) 10/12 (83.3%) 8/10 (80.0%) 0.019 2/8 (25.0%) 18/22 (81.8%) 0.007
CID off GC 11/30 (36.7%) 0/2 0/6 5/12 (41.7%) 6/10 (60.0%) 0.079 0/8 11/22 (50.0%) 0.014
CID off GC and no CTP change 8/30 (26.7%) 0/2 0/6 3/12 (25.0%) 5/10 (50.0%) 0.168 0/8 8/22 (36.4%) 0.071
  1. Also shown are all patients who achieved CID (regardless of GC), all patients who were off GC, and all patients who achieved CID off GC and did not change their CTP treatments, at 9 months. Patients lost to follow-up were considered treatment failures
  2. aIL1i: IL-1 inhibitor; IL6i: IL-6 inhibitor